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1.0 Introduction 
 
In May 2002, the United States Department of Energy (DOE) signed Assistance 
Instrument Number DE-FC09-02CH11109 with the Medical University of South 
Carolina (MUSC) to support the Environmental Biosciences Program (EBP).  This 
funding instrument replaces DOE Assistance Instrument Number DE-FC02-98CH10902. 
 
EBP is an integrated, multidisciplinary scientific research program, employing a range of 
research initiatives to identify, study and resolve environmental health risks.  These 
initiatives are consistent with the MUSC role as a comprehensive state-supported health 
sciences institution and with the nation’s need for new and better approaches to the 
solution of a complex and expansive array of environment-related health problems. 
 
The intrinsic capabilities of a comprehensive health sciences institution enable MUSC to 
be a national resource for the scientific investigation of environmental health issues.  
EBPs success as a nationally prominent research program is due, in part, to its ability to 
task-organize scientific expertise from multiple disciplines in addressing these complex 
problems 
 
Current research projects have focused EBP talent and resources on providing the 
scientific basis for risk-based standards, risk-based decision making and the accelerated 
clean-up of widespread environmental hazards.  These hazards include trichloroethylene,  
low-dose ionizing radiation (gamma and neutron) and alpha radiation from plutonium. 
 
Trichloroethylene research has been conducted as a joint collaborative effort with the 
University of Georgia. 
 
Work on the trichloroethylene research projects has been slowed as a result of funding 
uncertainties.  The impact of these funding uncertainties has been discussed with the 
DOE.  Laboratory work has been completed on several trichloroethylene risk assessment 
projects, and these projects have been brought to a close.  Plans for restructuring the 
performance schedule of the remaining trichloroethylene projects have been submitted to 
the department. A comprehensive manuscript on the scientific basis of trichloroethylene 
risk assessment is in preparation. 
 
Work on the low-dose radiation risk assessment projects is also progressing at a slowed 
rate as a result of funding uncertainties.  It has been necessary to restructure the 
proponency and performance schedule of these projects, with the project on Low-Dose 
Radiation: Epidemiology Risk Models transferred to DOE Office of Science proponency 
under a separate funding instrument.  Research on this project will continue under the 
provisions of the DOE Office of Science funding instrument, with progress reported in 
accordance with the requirements of that funding instrument.  Progress on that project 
will no longer be reported in quarterly reports for DE-FC09-02CH11109. 
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Following a meeting at the Savannah River Site on May 8, 2008, a plan was submitted 
for development of an epidemiological cohort study and prospective medical surveillance 
system for the assessment of disease rates among workers at the Savannah River Site 
(SRS).  This project will be incorporated into the ongoing project on Population Health 
Risks in the Vicinity of the Savannah River Site.  During a meeting at the SRS on 
October 21, 2008, a presentation was made on EBP participation in the development and 
operation of an Epidemiology Consortium at the SRS. A follow-up meeting with SRS 
officials is planned for 29 and 30 January 2009 at MUSC. 
 
An epidemiology project on population health risk assessment is being conducted to 
assess health risks among populations in the vicinity of the SRS.  This project is using the 
capabilities of the EBP GIS for the geographical assessment of cancer and non-cancer 
disease rates, as well as the potential association of population health risks with 
environmental exposures.  Although funding uncertainties have slowed progress on some 
aspects of this project, it has not been necessary to restructure the performance schedule 
to date. 
 
Questions, comments or requests for further information concerning the activities under 
this cooperative agreement can be forwarded to Dr. Lawrence C. Mohr in the EBP office 
of the Medical University of South Carolina at (843) 792-1532. 
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1.1 Summary and Significance of Research Projects 
 
Toxicology 
 
• Trichloroethylene (TCE) is the most prevalent and widespread chemical 
contaminant at DOE sites.  TCE is regulated as a human carcinogen based upon 
its hepatocarcinogenicity in a crude mouse model.  Very little is known about the 
molecular mechanisms of carcinogenesis and the human health effects of TCE.  
MUSC has developed a comprehensive research program on the molecular 
mechanisms of disease pathogenesis and the human health effects of TCE to 
better understand the risks to workers at DOE sites.  Through this research 
program, MUSC has helped to ensure that TCE risk assessment and TCE 
remediation activities are based upon sound science.  However, as a result of 
funding uncertainties, research on TCE risk assessment has been significantly 
slowed and several projects have been brought to completion.  Both the Medical 
University of South Carolina and the University of Georgia have provided 
institutional support for EBP investigators to publish the results of TCE risk 
assessment research performed through this cooperative agreement. 
 
Radiation Risk Assessment 
 
• The adverse health effects of both ionizing and non-ionizing radiation are of 
concern to DOE and the public.  Many important questions about the adverse 
human health effects of low-dose and low-dose rate radiation exposures remain 
unanswered – especially with respect to cancer risks.  MUSC has developed a 
comprehensive research program for the study of the effects of low-dose and low-
dose rate radiation exposures on human health.   Radiation risk assessment 
projects have included the development of biologically-based models of cancer 
risk and epidemiological models of health risks following low-dose radiation 
exposures. The project on epidemiological risk models will be conducted through 
a separate DOE Office of Science funding instrument in the future. A project is 
also being conducted on the assessment of both cancer and pulmonary fibrosis 
health risks following plutonium exposure. 
 
Population Risk Assessment 
 
• Population risk studies in areas surrounding DOE sites are of utmost importance 
to the department and to the citizens who live in these areas.  The Savannah River 
Region Health Information System is a very important national, regional, and 
DOE resource for the study of population health effects in the area surrounding 
the Savannah River Site (SRS).  In conjunction with the Savannah River Region 
Health Information System, MUSC has developed an extremely powerful 
Geographical Information System in which databases containing health, 
environmental, demographic and socioeconomic data can be integrated and 
analyzed for specific population health risks.  These capabilities are being used 
for the epidemiological assessment of both cancer and non-cancer health risks 
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among populations in the vicinity of the Savannah River Site.  A plan has been 
submitted to SRS for development on an epidemiological cohort study and 
prospective medical surveillance system for the assessment of disease rates 
among SRS workers.  In addition, planning has begun for EBP participation in the 
development and operation of an Epidemiology Consortium at the SRS. 
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1.2 Program Expenditures 
 
EBP Expenditure Summary  
 
The table below reflects expenditures by budgeted category recorded for the period 
October 2008 through December 2008 and includes the total life-to-date for Cooperative 
Agreement CH11109.   
 
 
 
Budget Category  Current Period                         LTD 
                      
Personnel   $ 77,000       
Supplies          269           ---         
Travel         ---                                                        --- 
Other         ---            ---                                 
Subcontract                                  ---                                                          --- 
Equipment                              ---            ---  
Total Direct Costs                  $ 77,269                                             $153                    
F & A      61,000                     $_71 
Total              $138                             $224 
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2.0 Program Management and Development Office 
 
The mission of the Program Management Office is to ensure that all projects of the 
cooperative agreement achieve their stated goals and objectives and are carried out in an 
efficient and cost-effective manner.  The executive leadership of the program has adopted 
a strategy-focused management approach that carefully aligns the resources and core 
competencies of the program with research priorities developed in coordination with 
DOE.  Specific Program Management responsibilities include workplan development, 
budget formulation, task organization of multidisciplinary research teams, financial 
management, progress reporting and program review. 
 
The Program Office reports to the Office of the Vice President for Academic Affairs and 
Provost.  Key faculty and staff members involved in Program Management are as 
follows: 
 
Principal Investigator and Director:  Lawrence C. Mohr, Jr., M.D. 
Co-Principal Investigator, Environmental    
Toxicology:      David Jollow, Ph.D. 
Co-Principal Investigator, Radiation     
Risk Assessment:     David G. Hoel, Ph.D. 
Co-Principal Investigator, Population    
Health Risk Assessment:    Daniel T. Lackland, Dr.P.H. 
Associate Director for Administration  
and Finance: Anita G. Jefferson, B.S. 
Administrative Coordinator:    Jill Canaday 
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3.0 Scientific Research 
 
3.1 Environmental Toxicology Research Projects 
 
3.1.1 Presystemic Elimination of Trichloroethylene and its Interactions with 
Alcohol: How Important are They at Environmental Exposure Levels? 
 
Project Director:     James V. Bruckner, Ph.D. 
 
Executive Summary 
 
Although extremely high doses of trichloroethylene (TCE) are required to produce 
tumors in mice and rats, there is concern on the part of the EPA and others that even trace 
(i.e., environmental) levels may present a cancer risk to humans.  The human body has a 
number of processes to protect against such low level toxic insults, including first-pass, 
or presystemic elimination.  Volatile organic chemicals (VOCs) such as TCE that are 
absorbed from the gut are subject to metabolism by the liver and exhalation by the lungs, 
before they reach the arterial circulation and are distributed systemically.  It has been 
theorized, but not demonstrated experimentally, that all of low oral doses of VOCs are 
removed by presystemic elimination.  It will be necessary to develop very sensitive 
analytical techniques in order to conduct experiments with environmentally-relevant 
levels of TCE.  Demonstration [experimentally and by physiologically-based 
pharmacokinetic (PBPK) modeling], that all of low oral doses of TCE are eliminated, 
would have a profound effect on extrahepatic cancer and non-cancer risk assessments of 
TCE. 
 
Alcohol (i.e., ethanol) and a number of other compounds are known to stimulate 
formation of increased amounts of cytochrome P450 2E1 (CYP2E1) in the liver.  
CYP2E1 is the key enzyme that initiates the oxidation of low doses of TCE to potentially 
mutagenic metabolites.  Thus it is reasoned that drinkers metabolically activate a greater 
percentage of their systemically-absorbed dose of TCE to carcinogenic metabolites.  
Similarly, populations with genetically-determined elevations of CYP2E1 might also be 
anticipated to be at increased risk.  The EPA uses this reasoning in their most recent 
health risk assessment of TCE, to support their choice of the most conservative (i.e., 
linear, no-threshold) mathematical model to predict cancer risks.  Preliminary PBPK 
modeling efforts suggest that elevated CYP2E1 activity will not result increased 
metabolism of low, environmentally-relevant doses of TCE.  Every human has CYP2E1 
activity far in excess of that necessary to metabolize all of low doses.  Since all of trace 
amounts of TCE are metabolized, it is reasonable to conclude that increased metabolic 
capacity due to alcohol, drugs, genetics, etc. is inconsequential.  Laboratory experiments 
and PBPK modeling will be carried out to prove this hypothesis. 
Relevance 
 
As described above, this research project is directly relevant to current and proposed EPA 
regulatory standards for drinking water contamination by TCE.  The EPA concludes, 
through both its cancer and non-cancer risk assessments (EPA, 2001), that exposure to 
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even minute levels of TCE is associated with low-level human risks.  It is concluded that 
certain subpopulations with genetically- or drug-induced elevations of P4502E1 (the 
enzyme responsible for formation of toxic metabolites of TCE) will be at significant risk.  
Preliminary research with other well-metabolized chemicals indicates that this is not true.  
The proposed research with alcohol should definitively establish this for TCE.  The 
second low-dose phenomenon to be investigated here will be presystemic, or first-pass 
elimination.  The liver and lungs act in concert to eliminate ingested VOCs before they 
reach the systemic/arterial circulation.  It is postulated that virtually all of trace levels of 
TCE in drinking water are removed, before they reach and present a hazard to 
extrahepatic target organs such as the lungs and kidneys.  Experiments have been 
designed and a PBPK model will be developed in collaboration with Dr. Fisher to 
characterize the capacity of this protective mechanism under different TCE exposure 
conditions. 
 
Objectives 
 
1. Develop and validate assays of TCE and its major metabolites in biological 
samples, including blood, tissues and urine.  The assays should be sufficiently 
sensitive to utilize in animal experiments employing very low doses of TCE. 
 
2. Accurately determine the capacity and dose-dependency of presystemic 
elimination of orally-administered TCE.  Characterize the influence of dose 
and dosage regimen on the systemic disposition/effects of TCE and related 
VOCs. 
 
3. Establish the influence (or lack thereof) of ethanol on the metabolic activation 
of low oral doses of TCE.  Determine whether the ratio of the metabolites 
trichloroacetic acid (potentially carcinogenic) and trichloroethanol (non-
carcinogenic) is altered by ethanol. 
 
Specific Aim 1. To determine the capacity and dose-dependency of presystemic 
elimination of ingested TCE and to delineate the relative contribution of the liver and 
lungs.   
 
Specific Aim 2. To establish the influence (or lack thereof) of ethanol on the 
metabolic activation of environmentally-encountered doses of TCE. 
 
Specific Aim 3.  To determine whether the ratio of the metabolites trichloroacetic 
acid (TCA) (potentially carcinogenic) and trichloroethanol (TCOH) is altered by co-
ingestion of ethanol. 
 
Quarterly Accomplishments 
 
Work on this project has been delayed as a result of an interruption in funding.  
Significant accomplishments to date are as follows: 
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1. One of our two original Specific Aims was to establish the influence (or lack 
thereof) of ethanol on the metabolic activation of trichloroethylene (TCE), 
including alteration of the ratio of its metabolites trichloroacetic acid (TCA) (a 
mouse carcinogen) and trichloroethanol (TCOH).  Experiments during the initial  
year of the project established that ethanol did indeed enhance the metabolism of 
relatively high doses of TCE to TCA and TCOH.  We hypothesized that induction 
of the hepatic cytochrome P450 (CYP) isozyme 2E1 (i.e., CYP2E1) would 
enhance the metabolism of high, but not low, environmentally-encountered doses 
of TCE.  Upon consideration of our results and experimental design, it became 
evident that ethanol was not only inducing CYP2E1, but altering alcohol and 
aldehyde dehydrogenases (ADH and ALDH), two enzymes responsible for  
conversion of the intermediate TCE metabolite, chloral hydrate, to TCOH and 
TCA.  Therefore, we chose to use pyridazine (PZ) rather than ethanol for the next 
phase of the project.  PZ is a potent CYP2E1 inducer, but has relatively modest  
effects on ADH and ALDH. 
 
2. Of particular importance to TCE risk assessment are two (2) important findings 
(1) PZ pretreatment resulted in a dose-dependent increase in the rate of TCE 
elimination, a substantial decrease in blood TCA levels and a modest increase in 
TCOH levels in TCE-dosed rats.  These alterations were pronounced in animals 
given 200 mg TCE/kg orally, but barely manifest at 10 mg TCE/kg, the lowest 
dosage administered.  These results support the aforementioned hypothesis about 
a lack of influence of CYP2E1 induction on low TCE doses.  A gas 
chromatography-mass spectrometry (GC-MS) method has been developed that 
will allow us to continue these experiments with much lower (i.e., 
environmentally-relevant) TCE exposures; (2) The marked reduction in blood 
TCA levels (noted above) in CYP2E1-induced animals implies that liver cancer 
risks may be lower under such conditions. 
 
3. The primary focus of our work on this project has been on clarifying the 
mechanistic basis for the substantial decrease in blood TCA concentrations in PZ-
induced rats. Progress on bringing this aspect of the project to completion has 
been delayed by funding uncertainties. 
 
4. The results of one study indicate that PZ pretreatment of rats results in a 
significant increase in the rate of clearance of TCA from the bloodstream.  Half-
lives (t½) of TCA in uninduced rats given 50 mg TCA/kg iv in two experiments 
were found to be ~800 and 930 minutes.  The t½ of TCA is much longer (3,300 
minutes) when it is formed as a metabolite in TCE-dosed animals.   This indicates 
that TCA is a rate-limited metabolite of TCE.  PZ-induced rats that received 50 
mg TCA/kg iv exhibited a TCA t½ of ~240 minutes (versus the 800- and 930-
minute t½s in uninduced rats).    This phenomenon may have resulted from:  
increased metabolism of TCA to dichloroacetic acid (DCA) and/or other 
metabolites; induction/activation of organic anion transporters in the kidneys; 
and/or displacement of TCA from plasma binding sites by PZ.   Equilibrium 
dialysis experiments have shown that PZ’s ability to displace TCA from rat 
 11 
plasma proteins is quite limited.  The highest PZ concentrations displaced only 
20% of bound TCA.  This alone cannot account for the pronounced increase in 
TCA clearance in vivo.  Experiments are planned to assess the influence of PZ on 
urinary elimination of TCA. 
 
5. A study has also been initiated conducted to learn whether PZ pretreatment 
influences: metabolism of CH to TCA versus TCOH; and conversion of TCOH to 
TCA.  In the latter case, rats were given 50 mg TCOH/kg iv, and blood TCA 
profiles monitored for a period of hours.  TCA concentrations in blood were 
substantially lower over time in PZ-induced rats than in uninduced rats.  This may 
be due to decreased metabolism of TCOH to TCA and/or increased urinary 
excretion of TCA.  In vitro experiments are planned to determine whether the 
former occurs.  Again, work on this aspect of the project has been significantly 
delayed because of funding uncertainties. 
 
6. New methodology for the determination of trace levels of trichloroethylene in 
biological samples using headspace solid-phase microextraction gas 
chromatography and negative chemical ionization mass spectrometry have been 
developed.  The efficacy of this technique has been demonstrated and research 
findings have been reported in the scientific literature, as previously reported. 
 
7. The project director has contributed to the writing of a comprehensive manuscript 
on the scientific basis of trichloroethylene risk assessment. 
 
 
Performance Schedule and Status of Aims 
 
Work on this project has been delayed because of an interruption in funding. 
 
The performance schedule of this project has been restructured as a result of funding 
uncertainties.  No significant changes in the specific aims of the project are anticipated.  
Data analysis and manuscript publication are continuing with institutional support from 
the Medical University of South Carolina and the University of Georgia.  A 
comprehensive manuscript on the scientific basis of trichloroethylene risk assessment is 
in preparation.  
 12 
 
3.1.2 PBPK Modeling of Toxic Metabolites of Trichloroethylene in Rats, Mice and 
Humans: Predicting the Health Risks Posed by Low Level Exposure to TCE 
 
Project Director:     Jeffery W. Fisher, Ph.D. 
 
Executive Summary 
 
Trichloroethylene (TCE) remains one of the most common ground water contaminants 
found in the US because of its disposal and use practices by the private sector, DOE and 
DOD.  The projected costs for remediation of TCE in the federal sector is well over $1 B.  
The health risks of TCE were recently reviewed by several scientists and published as a 
monologue in an Environmental Health Perspectives (EHP) Supplement (Vol. 108(2), 
2000).  Since the EHP publication on TCE, the US EPA released a draft ‘regulatory risk 
assessment for TCE’ to the authors of the EHP monologue and asked the authors to 
comment on their document.  In July 2002 the US EPA convened a scientific review 
panel to review their most recent draft TCE document. Physiologically based 
pharmacokinetic (PBPK) models were used as an aid in dose-response assessment (risk 
assessment) for cancer and non-cancer toxicological endpoints.  Five PBPK models were 
used on various human and rodents studies for cancer and non-cancer endpoints.  Several 
data gaps were identified as the US EPA attempted to use the PBPK models of Fisher, 
Clewell and Barton. In some cases the PBPK models were inappropriately or 
insufficiently exercised.  The objective of this project is to develop a single robust PBPK 
model for TCE for rodents and humans by incorporating new metabolic and kinetic data 
published since 1999, and by conducting limited critical metabolic and pharmacokinetic 
experiments in rodents to fill data gaps.  The refined PBPK model for TCE and 
metabolites in laboratory animals and humans will be exercised in an appropriate manner, 
and the results will be used to reduce the uncertainties associated with assessing the 
human health risks posed by low-level environmental exposure to TCE.   
 
Much progress has been achieved in understanding the quantitative aspects of 
metabolism of TCE in humans and rodents and in understanding the toxic and 
carcinogenic potential of the acid metabolites that are formed from metabolism of TCE.  
PBPK models have progressed from models that simply describing the parent chemical to 
PBPK models that contain sub models describing the formation and kinetics of 
metabolites such as trichloroacetic acid (TCA), trichloroethanol, chloral hydrate and in 
some cases, dichloroacetic acid.   Colleagues of mine and I have developed and published 
most of the PBPK models for TCE and metabolites in humans and rodents with financial 
support from the USAF, US EPA and Strategic Environmental Research and 
Development Program (SERDP).  The US EPA used early-unpublished versions of our 
most recent PBPK models for mice and humans in their current draft risk assessment 
document.   
 
Relevance 
The scientific issues related to determining the health risks posed by low levels of TCE in 
the environment are relevant to many other solvents found in water supplies.  If sound 
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science and extrapolation methodology can be demonstrated for this chemical, then other 
chemicals can be evaluated in a similar manner.   This could lead to a potential saving of 
multiple millions of dollars in unnecessary clean-up costs. 
 
Objectives 
 
1. Harmonize current PBPK models used by the US EPA into one PBPK model for 
TCE and metabolites.  Incorporate newly published and unpublished data in 
humans and rodents.  New data sets include published and unpublished rat data on 
first pass metabolism of TCE from the laboratory of Dr. Jim Bruckner at the 
University of Georgia, published human and unpublished rat data on glutathione 
conjugation of TCE [(S-(1,2-Dichlorovinyl) Glutathione (DCVG)] obtained by 
Dr. Larry Lash at Wayne State University, and published Epidemiology studies 
performed in Europe, where urinary excretion of TCA was quantified.  
 
2. Conduct laboratory studies to refine PBPK model predicted dose metrics in 
laboratory animal and humans that will be used in the formulation of the final 
product of this project, namely a TCE human health risk assessment.  Determine 
the stoichiometric yield of DCVG for relevant doses of TCE in rats.  Information 
on DCVG will provide data to develop the DCVG pathway in a PBPK model for 
TCE and to offer plausible dose-metrics that can be associated with the risk of 
kidney cancer in humans.   Colleagues and I have time course data for DCVG in 
humans exposed to TCE vapors [Lash, LH, DA Putt, WT Brashear, R Abbas, J 
Parker and JW Fisher. 1999. Identification of S-(1,2-Dichlorovinyl) Glutathione 
in the Blood of Human Volunteers Exposed to Trichloroethylene. Toxicol. 
Environ. Health Part A, 56, 1-21].   
 
3. Conduct laboratory studies to evaluate how much dichloroacetic acid (DCA) is 
formed metabolically from TCE.  This minor metabolite remains an important 
risk assessment issue because of its carcinogenic potency and the requirement that 
the US EPA account for cumulative risks.  DCA is the number one by-product 
from chlorination of water. Thus, to account for the health risks poised by TCE in 
drinking water, the health risks from exposure to DCA itself must be quantified 
and accounted for in the health risk assessment of TCE. 
 
4. Perform a cancer and non-cancer risk assessment for TCE using the harmonized 
single PBPK model for TCE and metabolites. The risk assessment will rely on 
‘mode of action’ hypotheses and theoretical assumptions for low dose 
extrapolations. Relevant human data sets will be incorporated into the analyses.  
 
Specific Aim 1. To harmonize current PBPK models used by the US EPA into one 
PBPK model for TCE and metabolites by incorporating newly published and unpublished 
data in humans and rodents. 
 
Specific Aim 2. To examine the metabolism of TCE in rodents with emphasis on 
the dose-dependence of conversion of TCE to DCVC. 
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Specific Aim 3. To re-examine the dose-dependence of conversion of TCE to DCA 
in laboratory animals. 
 
Specific Aim 4. To perform a cancer and non-cancer risk assessment for TCE using 
the harmonized single PBPK model for TCE and metabolites. 
 
Quarterly Accomplishments 
 
Work on this project has been delayed as a result of an interruption in funding.  
Significant accomplishments to date are as follows: 
 
1. Human Dichloroacetic acid PBPK model: A model structure and metabolic 
descriptions of DCA were patterned after work in our laboratory with the 
development of a PBPK model for DCA in rats and mice. The Michaelis-Menten 
affinity constant for GSTz (Km) and enzyme degradation rate (Kde) in the model 
were fixed. The initial maximum velocity of GSTz for metabolism of DCA (Vmaxc), 
the non-metabolism loss rate (Kfc), inhibition rate (kd) and oral absorption rates were 
estimated through fitting DCA blood kinetic data sets from different human clinic 
studies.  
 
Several published kinetic studies exist for DCA. Additionally, we are using new 
unpublished low dose pharmacokinetic data collected with 8 males and 8 females 
under an EPA grant at Battelle NW. These individuals were given a single iv dose 
(0.3 mg/kg) followed by a 2 mg/kg oral dose at the beginning of the study and then 
repeated14 days later.  The subjects drank 0.02 mg/kg DCA for 14 consecutive days 
between the two doses.  
 
The human DCA kinetic model suggests the polymorphic forms of GSTz and oral 
absorption rates influence the kinetics of DCA. Our simulations also suggest that 
DCA is degraded by another unknown metabolic pathway as proposed in our DCA 
modeling with rats and mice. 
 
2. Two trichloroacetic acid (TCA) modeling papers are being finalized for publication to 
journals. One paper describes the influence of serum protein binding on the dosimetry 
of TCA in liver of mice and humans. The other paper evaluates the pharmacokinetic 
evidence that TCA is the primary metabolite responsible for liver tumors in mice. 
 
3. A quantitative evaluation of the kinetics of dichloroacetic acid in humans has been 
completed. 
 
4. A physiologically-based pharmacokinetic model for dichloroacetic acid and its 
potential role in human toxicity has been completed.  The results of this investigation 
have been published in the scientific literature, as previously reported. 
 
5. The project director has contributed to the writing of a comprehensive manuscript on 
the scientific basis of trichloroethylene risk assessment. 
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Performance Schedule and Status of Aims  
 
Work on this project has been delayed because of an interruption in funding. 
 
The performance schedule of this project has been restructured as a result of funding 
uncertainties.  No significant changes in the specific aims of the project are anticipated.  
Data analysis and manuscript preparation are continuing with institutional support from 
the Medical University of South Carolina and the University of Georgia.  A 
comprehensive manuscript on the scientific basis of trichloroethylene risk assessment is 
in preparation. 
 
 
3.2 Radiation Risk Assessment Projects 
 
3.2.1 Low Dose Radiation: Biologically-Based Models of Cancer Risk 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
The use of experimental animals in radiation risk estimation is especially important for 
those situations when human data are inadequate or unavailable.  This is particularly true 
for neutron exposures and low-dose rate exposures to gamma and x-ray.  The purpose of 
this project is to apply biological based models to radiation risk estimation using 
experimental data.   
 
The important questions to be answered are 1) whether or not non-cancer effects such as 
cardiovascular disease (CVD) are effected by low doses of radiation. 2) What is the 
increase in risk for a equivalent dose of alpha or neutron compared to gamma or x-ray? 3) 
Is the risk of chronic radiation exposure the same as that of acute exposure of both high 
LET (alpha, neutron) and low LET (gamma, beta, x-ray) exposures.  4) Are cancer and 
non-cancer effects present at low doses of radiation (neutron, alpha and gamma)? 
 
Relevance 
 
By comparing the two stage clonal expansion models for cancer with the in vivo 
experimental data, the investigators will not only increase understanding of cancer 
development following low-dose radiation exposure, but also add biological credibility. 
This approach will provide a method for answering the important environmental question 
of whether risks are decreased with decreasing dose-rate, a key issue for chronic radiation 
control of workplace exposures.  Further, the effects of neutron and alpha exposure at 
low-doses is of importance to radiation workers. 
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Objectives 
 
The objective of this project is to determine the effects of dose-rate and radiation type on 
the development of various cancer types following low-dose radiation exposures. Two-
stage biologically based risk models will be used for analysis and compared with the 
results from traditional methods of analysis. Using previously validated data, assumptions 
made about the biological effects of ionizing radiation can be used in the two-stage model 
to predict dose-rate effects on the development of various cancers following low-dose 
exposures.  Additionally non-cancer effects such as cardiovascular disease will be 
estimated at low doses of radiation. 
 
Specific Aim 1. To use the large Argonne National Laboratory Janus mouse study 
to answer basic questions concerning dose-rate and radiation type effects on cancer.  This 
involves over forty thousand mice exposed acutely and chronically at several doses with 
both gamma or neutron exposures. 
 
Specific Aim 2. To use the data from new studies at the Bologna Institute of 
Oncology (Italy) on gamma exposed Spague-Dawley rats.  This data will provide for the 
estimation of low-dose effects of gamma exposures.  These studies involve both acute 
and chronic exposures. 
 
Specific Aim 3. To use this data from the Harwell Laboratory (U.K.), which 
involves alpha and beta radiation by inhalation and injection exposures to mice.  These 
studies provide an accurate comparison of the cancer effects of alpha exposure to that of 
beta. 
 
Quarterly Accomplishments 
 
1. Data analysis using the two-stage clonal expansion (TSCE) model is progressing.  
We are applying the TSCE model to available mouse data from the Argonne 
National Laboratory to operate improved cancer risk estimates for gamma and 
neutron exposed animals.  A  manuscript has been completed and is undergoing 
revision prior to submission. 
 
2. Analyses of lung, liver and bone cancer incidence in beagle dogs after exposure 
via inhalation to 238PuO2 and 239PuO2 using a multistage cancer model are 
completed and a draft manuscript is being edited for submission to Mathematical 
Biosciences.   
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
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3.2.2 Health Risks of Plutonium Exposures 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
Human data on health risks associated with internal exposure to radionucleides (by 
inhalation and/or ingestion) is limited. With regard to plutonium exposures, there have 
been two DOE worker studies and, more recently, several studies of Russian nuclear 
workers (Mayak). One of the DOE worker cohorts (Rocky Flats) contains data that may 
be very useful in understanding the carcinogenic effects of low-dose plutonium exposure. 
In contrast to the paucity of human data, there is a considerable amount of experimental 
data related to the development of cancer in rats and dogs following plutonium 
inhalation. A statistical model of cancer risk following low-dose plutonium exposure is 
becoming increasingly important with respect to planned DOE material disposition 
activities, both domestic and international. For example, plans to eliminate surplus U.S. 
plutonium during the next two decades, through the irradiation of mixed oxide fuel and 
the conversion of a certain portion of the material to an immobilized waste form, 
represent significant program initiatives. It is particularly important for potential health 
effects of these initiatives to be investigated and to be incorporated into evolving 
statistical risk models.  U.S. data will be related to prior studies of the Mayak workers 
which have consistently shown a higher level of lung, liver and bone cancer in 
comparison to U.S. workers.  Pulmonary fibrosis is also a risk from the inhalation of 
plutonium; factors related to this risk will be assessed through the analysis of available 
animal and human data. 
 
Relevance 
 
The processing and storage of plutonium requires a quantitive understanding of the health 
risks of plutonium, particularly in the low-dose range. Furthermore, DOE workers who 
may be exposed to plutonium should be monitored with a state-of-the-art medical 
surveillance program that includes the use of validated biomarkers. 
 
Objectives 
 
1. The general problem we are considering is the evaluation and protection of the 
health of DOE workers in their handling of plutonium at the SRS and other DOE 
facilities. The project will develop risk models of the cancer and non-cancer 
health effects of low dose plutonium exposures, to include low-dose exposures by 
inhalation or ingestion.  These risk models will be used for the subsequent 
development of an appropriate medical and environmental surveillance system. 
 
2. The first step is a quantitative evaluation of the human and animal data so that we 
have good productive risk models.   
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3. We will develop a medical and environmental surveillance system which includes 
the use of urine analyses for the measurement of internal plutonium levels.  
 
Specific Aim 1. To develop human risk models for cancer and non-cancer health 
effects of plutonium exposure, to include low-dose exposures by inhalation or ingestion. 
  
Specific Aim 2.  To develop a medical and environmental surveillance system for 
DOE workers who may be exposed to plutonium, to include low dose exposures by 
inhalation or ingestion.  This system will be based upon the risk models developed in 
Specific Aim 1. 
 
Quarterly Accomplishments 
 
1. Analyses of lung fibrosis and lung cancer incidence using data on beagle dogs 
exposed via inhalation to 238PuO2 and 239PuO2 have been completed.  A 
manuscript will appear in the March issue of Health Physics. 
 
2. Analyses of lung, liver and bone cancer mortality in beagle dogs exposed to 
238PuO2, 239PuO2, and 239Pu(NO3)4 based on models derived from data on 
human exposures at the Mayak Production Association have been conducted.  A 
manuscript has been drafted and is undergoing revision.   
 
3. A biologically-based two-stage clonal expansion model for cancer risk has been 
applied to the plutonium exposed beagle dog lung cancer data and a draft 
manuscript has been completed. 
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
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3.3 Population Health Risk Assessment Project 
 
3.3.1 Population Health Risks in The Vicinity of the Savannah River Site  
 
            Project Director:  Daniel Lackland, Dr.P.H. 
 
Executive Summary 
 
We have developed the infrastructure, resources and technical expertise necessary to 
conduct epidemiological assessments of population health risks using a geographical 
information system (GIS). Our sources include the following: 
 
Savannah River Region Health Information System (SRRHIS) 
The geographic cancer registry incorporates 25 counties around the Savannah River Site.  
Cancer incidence data obtained in a high quality manner is an essential component of 
epidemiological investigations. 
 
A direct link to this resource has been established in which cancer cases are 
geographically identified and incorporated in the data analysis. SRRHIS provides the 
cancer-related component of the assessment system. Cancer incidence and mortality rates 
are analyzed with respect to various aspects of population characteristics, demographic 
data and environmental exposures. 
 
Geo-coding System 
The ability to ascertain and analyze health-related, environmental, and socio-economic 
data for small areas, such as a census block, is an essential component of epidemiological 
investigation. A Geographic Information System (GIS) defines geographic study areas by 
organizing small areas such as census blocks. The system consists of computerized 
databases structured to a defined geographic area combining the tools for thematic map 
generation, proximity analysis, buffer zone identification and map overly comparisons.   
 
A critical component of any GIS is the ability to “address match” other databases into the 
system. An efficient GIS with a high match record must incorporate a system to add new 
addresses and changes, which requires an elaborate system of updates. In addition to 
collecting new data, epidemiological investigations are greatly enhanced with the use of 
existing data, saving money and time. Such databases, however, must be comprehensive 
and include multiple health outcomes, co-morbidities, indicators of socio-economic 
status, environmental exposures and population demographics and characteristics. 
 
The analytical assessment of disease patterns constitutes a critical stage in the 
investigation of the environmental etiology of disease. The assessment involves the use 
of resources such as the GIS and multiple databases. Analyses involve a complex and 
sophisticated quantitative methodology. 
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Existing Databases 
The Project has established access links to various health and environmental data bases 
including the SC Medicaid and Medicare data bases, hospital discharge and billing data, 
census TIGER files, as well as data and tissue specimens from cohort studies such as the 
Evans County Heart Study. The Project also maintains the capability to collect new data 
and tissue samples. 
 
Objectives 
 
1. To develop a comprehensive population risk assessment system and associated 
protocols. 
 
2. To conduct several epidemiology risk assessments of populations in the vicinity 
of the Savannah River Site (SRS) using the resources of the comprehensive 
system. 
 
3. To establish and maintain a state-of-the-art information system that interfaces 
with the agencies and custodians of health, environmental, geographic 
demographic and economic databases in order to provide more accurate and 
comprehensive population risk assessment. 
 
Specific Aims 
 
Specific Aim 1.  To continue to develop and enhance the Geographic Information 
System as a tool for the conduct of population risk studies. 
 
Specific Aim 2.  To continue the analysis of population cancer risks in the vicinity 
of the Savannah River Site (SRS). 
 
Specific Aim 3.  To assess population health risks in relation to specific 
environmental hazards at SRS and other DOE sites. 
 
Specific Aim 4. To assess health risks of former workers at the Savannah River 
Site. 
 
Quarterly Accomplishments 
 
1. Refined and modified manuscript regarding multiple exposures from former SRS 
workers. 
 
2. Developed maps of lupus in SC and maps of relevant environmental exposures.  
Have begun the analysis of lupus rates among populations in the vicinity of SRS. 
 
3. Completion of an assessment of cardiovascular disease and aortic calcification for 
former SRS workers. 
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4. Planned manuscripts and abstracts include: 1] an assessment of population disease 
rates and the cardiovascular disease rates of former SRS workers; 2] an 
assessment of environmental exposures and disease rates of lupus among 
populations in the vicinity of SRS; 3] cardiovascular disease among retires SRS 
workers; 4] assessment of multiple environmental exposures among former SRS 
workers. 
 
Performance Schedule and Status of Aims 
Neither the performance schedule nor the status of aims has changed. 
 
